Chloroquine is NOT recommended for psoriatic arthritis
Chloroquine and hydroxychloroquine are explicitly not recommended for use in psoriatic arthritis according to current treatment guidelines 1. This represents a clear consensus across multiple international guideline bodies.
Why Chloroquine Should Be Avoided
The 2009 treatment recommendations from the Annals of the Rheumatic Diseases explicitly state: "Gold salts, chloroquine and hydroxychloroquine also are not recommended for use in PsA" 1. This recommendation has been consistently maintained across guideline updates.
Key Safety Concerns
Risk of psoriasis exacerbation: Chloroquine can precipitate severe attacks of psoriasis. The FDA drug label specifically warns that "use of chloroquine phosphate tablets in patients with psoriasis may precipitate a severe attack of psoriasis" and states the drug "should not be used in these conditions unless the benefit to the patient outweighs the potential risks" 2. Chloroquine may also exacerbate the condition and can worsen psoriasis 2.
Documented adverse reactions: While some older research suggested chloroquine might be tolerated 3, 4, 5, case reports document severe cutaneous reactions including exfoliative erythroderma occurring as early as 11 days after initiation 6. One review concluded that antimalarials in psoriatic patients are "associated with a high incidence of severe cutaneous adverse reactions" and "should not be used in psoriatic patients if other less toxic, effective therapies are available" 6.
Current Recommended Treatment Approach
The most recent 2024 EULAR guidelines 7 and 2019 ACR/NPF guidelines 8 provide a clear treatment algorithm that does NOT include chloroquine:
For Peripheral Arthritis:
- First-line: NSAIDs for symptom relief 9
- Second-line: Conventional synthetic DMARDs (csDMARDs) - specifically methotrexate (preferred with skin involvement), sulfasalazine, or leflunomide 9, 7
- Third-line: Biologic DMARDs (TNF inhibitors, IL-17 inhibitors, IL-12/23 inhibitors) 9
- Fourth-line: JAK inhibitors or PDE4 inhibitors 9, 7
Critical Pitfall to Avoid
Do not confuse the limited positive findings in older research studies 3, 4 with current guideline recommendations. While these studies suggested some patients tolerated chloroquine, they predate modern treatment options and the formal guideline consensus against its use. The risk-benefit ratio is unfavorable when safer, more effective alternatives exist.
Bottom Line
Use methotrexate, sulfasalazine, or leflunomide as your first-line DMARD therapy for psoriatic arthritis 9, 7. Chloroquine has no role in the modern treatment algorithm and carries specific risks of worsening the underlying psoriatic skin disease.